Publikationen von Udo Reichl
Alle Typen
Poster (356)
641.
Poster
The secrets of “OP7”, an influenza DIP: mathematical model, impact of mutations and antiviral mechanisms. 9th European Congress of Virology (ECV), Cavtat/Dubrovnik (Croatia) (2025)
642.
Poster
Genetically engineered defective interfering particles for antiviral treatment and vaccination. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
643.
Poster
HCD Perfusion of CCX.E10 Quail Cells for Production of Vesicular Stomatitis Virus based oncolytic Vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)
644.
Poster
Production of Oncolytic rVSV-NDV in CCX.E10 Quail Cells by HCD Perfusion Culture. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)
645.
Poster
Production of Oncolytic Newcastle Disease Virus in EB66 cells. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
646.
Poster
Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. 28th ESACT Meeting , Edingburgh (Scotland) (2024)
647.
Poster
Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)
648.
Poster
Defective Interfering Particles of Influenza A Virus As Broad-Spectrum Antivirals. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
649.
Poster
Mechanisms of antiviral action of the influenza defective interfering particle “OP7”. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
650.
Poster
Mechanisms of antiviral action of the influenza defective interfering particle “OP7”. 28th ESACT Meeting, Edinburgh (Scotland) (2024)
651.
Poster
A two-dimensional model to predict coinfection of influenza A virus with defective interfering particles in tissue-like systems. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)
652.
Poster
Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
653.
Poster
Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
654.
Poster
In-depth N glycoproteomic analysis reveals strategies to elucidate unanticipated N glycans in the low-abundant human blood plasma N glycoproteome. 23rd Human Proteome Organization World Congress (HUPO World Congress), Dresden (Germany) (2024)
655.
Poster
Development of a cell-free multi-enzyme cascade for the synthesis of CDP-glycerol. GlycoBioTec 2023, Berlin, Germany (2023)
656.
Poster
Development of a cell-free enzymatic cascade for the synthesis of GDP-fucose - modeling and optimization. GlycoBioTec 2023, Berlin, Germany (2023)
657.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
658.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8th European Congress of Virology, Gdańsk (Poland) (2023)
659.
Poster
Multi-gram-scale production of uridine nucleotide sugars by in-vitro multi-enzyme cascades. GlycoBioTec 2023, Berlin, Germany (2023)
660.
Poster
Development of an in-vitro multi-enzyme cascade for the synthesis of uridine diphosphate N-acetylgalactosamine using a DoE approach. GlycoBioTec 2023, Berlin, Germany (2023)